Hilab
Latest round
- Series B
Last raised
- Jan 2023
Total raised
- $14M
Investors
- 7
About Hilab
Founded in 2004 in Curitiba, Brazil, Hilab offers advanced diagnostic technologies for point-of-care testing. Recently, the company expanded its operational capabilities but, as of August 2024, has discontinued its operations.Hilab provides a range of point-of-care diagnostic solutions, including a compact blood count device that delivers results in 25 minutes and a multi-method device utilizing immunochromatography and fluorescence. Their offerings also feature an electrochemical device with results in under eight minutes and a molecular biology device comparable to RT-PCR, providing outcomes within one hour.Hilab's operations were discontinued as of August 2024, and, consequently, there are no forthcoming products or market expansion plans to discuss.
Who invested in Hilab
7 investors across 3 rounds
See all investors in Hilab
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hilab
Who invested in Hilab?
Hilab has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hilab raised?
Hilab has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hilab last raise money?
Hilab's most recent round on record is a Series B, in Jan 2023.
What does Hilab do?
Founded in 2004 in Curitiba, Brazil, Hilab offers advanced diagnostic technologies for point-of-care testing.
Where is Hilab headquartered?
Hilab is headquartered in Curitiba, Brazil.
Which VCs invest in companies like Hilab?
Among active investors with capital left to deploy, Crescera Capital, Kaszek Ventures, Anti Fund and Kinea Investments back medical devices & equipment companies at Hilab's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Hilab? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.